TP53 and breast cancer: Similar inhibitory effects of Hinokiflavone on MDM2 and p53 ubiquitination were also observed in breast cancer MCF7 cells that have wild-type p53, and on MDM2 ubiquitination in leukemia HL60 cells with p53 deletion, further supporting Hinokiflavone’s role as a potential MDM2 inhibitor (Figure S3).